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Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer.
Most patients present with advanced disease at diagnosis, which only per-
mits palliative chemotherapeutic treatments. RNA dysregulation is a hall-
mark of most human cancers, including PDAC. To test the impact of
RNA processing dysregulation on PDAC pathology, we performed a bioin-
formatics analysis to identify RNA-binding proteins (RBPs) associated
with prognosis. Among the 12 RBPs associated with progression-free sur-
vival, we focused on MEX3A because it was recently shown to mark an
intestinal stem cell population that is refractory to chemotherapeutic treat-
ments, a typical feature of PDAC. Increased expression of MEX3A was
correlated with higher disease stage in PDAC patients and with tumor
development in a mouse model of PDAC. Depletion of MEX3A in PDAC
cells enhanced sensitivity to chemotherapeutic treatment with gemcitabine,
whereas its expression was increased in PDAC cells selected upon chronic
exposure to the drug. RNA-sequencing analyses highlighted hundreds of
genes whose expression is sensitive to MEX3A expression, with significant
enrichment in cell cycle genes. MEX3A binds to its target mRNAs, like
cyclin-dependent kinase 6 (CDK6), and promotes their stability. Accord-
ingly, knockdown of MEX3A caused a significant reduction in PDAC cell
proliferation and in progression to the S phase of the cell cycle. These find-
ings uncover a novel role for MEX3A in the acquisition and maintenance
of chemoresistance by PDAC cells, suggesting that it may represent a novel
therapeutic target for PDAC.
Abbreviations
CLIP, UV-crosslink and RNA immunoprecipitation; DFS, disease-free survival; DR, drug resistant; EMT, mesenchymal transition; MC, MITO-
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one the
most lethal human tumors, with 5-year survival rate
< 9% [1,2]. Late diagnosis and/or early development
of metastases strongly limit therapeutic options for
PDAC patients. Despite advances in surgery and
chemotherapy, prognosis has only slightly improved
over the past decade. Thus, identification of early
biomarkers and development of novel therapies repre-
sent clinical priorities for this disease [3].
Recent genome-wide analyses of cancer cell tran-
scriptomes have shown profound dysregulation of gene
expression programs, particularly at the level of RNA
processing [4,5]. Cancer cells often express transcript
variants that are not present in normal cells, which
can generate protein isoforms conferring growth
advantage over the host tissue [5]. In some cases, dys-
regulation of RNA metabolism in cancer cells is asso-
ciated with somatic mutations in the target genes [6].
However, aberrant expression or activity of regulatory
RNA-binding proteins (RBPs) can also alter RNA
metabolism in cancer [7]. Most RBPs recognize specific
sequences in the RNA and contribute to regulation of
the human transcriptome. They generally act coopera-
tively by forming dynamic ribonucleoprotein (RNP)
complexes, which modulate nuclear RNA processing
and export to the cytoplasm, as well as stability, trans-
lation, and decay of mature transcripts in the cyto-
plasm [8,9]. Thus, changes in the expression or activity
of RBPs can directly lead to genome-wide changes in
the cell transcriptome and proteome, which impact on
oncogenic features and chemoresistance of cancer cells
[10,11].
Dysregulation of RNA metabolism can be also
induced by chemotherapeutic treatments, hence sup-
porting evolution of the tumor toward more resistant
phenotypes [12]. In the case of PDAC, it was shown
that gemcitabine, one of the first-line drugs for this
cancer, induces the expression of two multifunctional
RBPs, SRSF1 and PTBP1, which in turn enhance
survival to chemotherapeutic treatments through
alternative splicing regulation. Short-term exposure
of PDAC cells to gemcitabine induces the expression
of SRSF1 and splicing of the pro-oncogenic MNK2b
variant [13]. Moreover, chronic treatment with this
drug caused the selection of clones that overex-
pressed PTBP1, which promotes aerobic glycolysis
through splicing of the PKM2 isoform of pyruvate
kinase [14]. Chemotherapy response could also be
modulated by alternative polyadenylation of selected
transcripts. The transcription factor ZEB1 is a mas-
ter regulator of epithelial to mesenchymal transition
(EMT) that is associated with resistance to
chemotherapy and with poor prognosis in PDAC
[15]. Treatment of PDAC cells with gemcitabine
caused shortening of the 30 untranslated region by
alternative polyadenylation. This regulation abolished
ZEB1 translational repression by microRNAs, thus
yielding higher protein levels [16]. Notably, enhanced
PDAC tumorigenicity by loss of microRNA control
through alternative polyadenylation has been recently
observed on genome-wide scale by analysis of a
cohort of 148 PDAC patients [17], supporting the
pathological relevance of this process in the disease.
Lastly, control of mRNA stability by specific RBPs
also contributes to PDAC growth and progression.
For instance, treatment of PDAC cells with PARP
inhibitors (PARPi), which are approved as mainte-
nance treatment of patients with BRCA-mutated
metastatic PDAC after response to platinum-based
chemotherapy [18], was shown to induce the cyto-
plasmic translocation of HuR. In the cytoplasm,
HuR stabilizes the poly (ADP-ribose) glycohydrolase
(PARG) mRNA and enhances DNA repair. On the
contrary, silencing of HuR increases the efficacy of
PARPi in PDAC cell and mouse models [19]. These
observations highlight the relevance of changes in
RBP expression for PDAC tumorigenesis. Neverthe-
less, a comprehensive view of the impact of RBPs
on PDAC prognosis is still lacking.
Herein, to evaluate the prognostic value of RBP
expression in PDAC, we carried out a bioinformatics
screening of The Cancer Genome Atlas (TGCA) data-
base. Out of 12 genes that were associated with dis-
ease-free survival (DFS) in PDAC patients, we focused
on MEX3A because its expression was associated with
a subpopulation of intestinal stem cells that is refrac-
tory to chemotherapeutic treatments [20]. Further-
more, it was recently reported that high expression of
MEX3A correlates with advanced PDAC stage and
worse prognosis in patients, indicating its oncogenic
function in this cancer [21]. Accordingly, we found
that MEX3A expression correlates with resistance to
gemcitabine in PDAC cells and with pancreatic
tumorigenesis in PDAC patients and mice. RNA-se-
quencing analysis of MEX3A-depleted cells identified
cell cycle progression as a functional process regulated
by this RBP. Our data show that MEX3A promotes
the expression of CDK6, a kinase required for the G1-
S transition with strong therapeutic relevance for
PDAC [22], while MEX3A depletion significantly
impairs S phase entry and cell proliferation. These
findings suggest that MEX3A represents a key onco-
genic factor and new potential therapeutic target for
PDAC treatment.
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2. Materials and methods
2.1. Cell culture, transfections, and treatments
MiaPaCa-2, ASPC1, C5M2 cells were cultured in
DMEM medium (Sigma D5796, Darmstadt, Germany)
supplemented with 10% fetal bovine serum (Gibco,
Waltham, MA, USA), Non-Essential Amino Acids
1009 (Thermo Fisher 11140035, Waltham, Mas-
sachusetts, USA), and gentamicin 2009 (Thermo
Fisher 15710-049). HPAF-II and Pt45P1 were cultured
in RPMI 1640 medium (Euroclone ECM2001L, Milan,
Italy) supplemented with 10% fetal bovine serum,
Non-Essential Amino Acids 1009, and gentamicin
2009. Cells were grown in a 37 °C humidified atmo-
sphere of 5% CO2.
To generate drug-resistant (DR) clones, we exposed
MiaPaCa-2 cells to treatment with gemcitabine (1 lM)
for 7 days. At the end of treatment, surviving clones
were amplified and recurrently treated with the drug to
maintain the selection. The Pt45P1-DR clones were
generated previously in our laboratory [14].
MiaPaCa-2 cells were transfected with FLAG or
FLAG-MEX3A plasmids using Lipofectamine 2000
(Invitrogen, Carlsbad, California, USA). For RNAi,
cells were transfected with 100 nM siRNAs using Lipo-
fectamine RNAi Max (Invitrogen) and Opti-MEM
medium (Invitrogen). SiRNA for MEX3A (siMEX3A-
1) are sense 50-GUGUUUCCCUUCACUCUCUdTd
T-30 and antisense, 50-AGAGAGUGAAGGGAAA
CACdTdT-30 (Sigma), whose sequences are taken from
paper of Jiang H. [23] MEX3A On target plus smart-
pool siRNAs (siMEX3A-sp) were purchased from
Dharmacon (Lafayette, Colorado, USA).
MiaPaCa-2 cells were synchronized by incubation
with 0.5 mM mimosine (Sigma) for 18 h [24]. Cells
were then washed three times with PBS and collected
at the times indicated in figures. Gemcitabine (Eli Lilly
& Company, Indianapolis, IN, USA) was dissolved in
water and stored at –20 °C for up to one month.
2.2. Mouse strains
All animal studies were approved by the Institutional
Animal Care of the Regina Elena National Cancer
Institute and by the Government Committee of
National Minister of Health and were conducted
according to EU Directive 2010/63/EU for animal
experiments. LSL-KrasG12D/+ mice and Pdx-1-Cre
transgenic mice [25,26] were interbred with FVB
MITO-Luc reporter mice [27] to obtain MITO; LSL-
KrasG12D/+; Pdx-1-Cre. The LSL-KrasG12D/+ lin-
eage was maintained heterozygous state [28].
After genomic DNA extraction of tail biopsies, posi-
tive founder animals were identified by PCR using pri-
mers specific for the transgenes (Table S1).
2.3. Bioluminescence imaging
Mice (24–28 weeks old) were anesthetized, and
75 mgkg1 of D-luciferin (Caliper, Perkin Elmer, Wal-
tham, Massachusetts, USA) was injected intraperi-
toneally. Ten minutes later, quantification of light
emission was acquired for 5 min. Signal was detected
using the IVIS LuminaII CCD camera system and
analyzed with the Living Image 2.20 software package
(Caliper Life Sciences, Waltham, Massachusetts,
USA). Photon emission was measured in specific
regions of interest (ROIs). Data were expressed as
photonsecond1cm2steradiant1 (ps1cm2sr1).
After sacrifice, pancreas was resected and analyzed for
bioluminescence imaging (BLI) ex vivo. The intensity
of bioluminescence was color-coded for imaging pur-
poses; the scale used in the experiment is reported in
the figures.
2.4. Bioinformatics analysis
Analysis of RBPs associated with PDAC prognosis
was performed by screening ‘The Cancer Genome
Atlas (TCGA)’ database. Expression of mRNAs
detected by the RNA-sequencing analysis of Pancreatic
Adenocarcinoma (TCGA, Firehose Legacy) was down-
loaded from cBioPortal (https://www.cbioportal.org/
study/summary?id=paad_tcga). Disease-free survival
(DFS) was evaluated by using Kaplan–Meier analysis
and multivariate Cox proportional hazard regression
model. The log-rank test was used to assess differences
between curves. Patients with high signal intensity and
low signal intensity were defined by considering posi-
tive and negative z-score values. Significance was
defined at the P < 0.05 level. Analyses were performed
with MATLAB R2019 or CBIOPORTAL tool (https://www.
cbioportal.org/study/summary?id=paad_tcga). Annota-
tion of high-purity PDAC samples in basal or classic
subtype was retrieved from TCGA Research Network
[29]. Analysis for differential expression of RBPs
between these subtypes was performed using the visual
interface of the PSICHOMICS R package [30]. Correlation
of MEX3A expression with markers of either basal or
classic PDAC subtype was performed using the
cBioPortal database. Association of RBP expression
with PDAC stage was analyzed with the R2 genomics
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platform (http://r2.amc.nl – Tumor Pancreatic adeno-
carcinoma -TCGA-178-rsem-tcgars).
2.5. RT-PCR and qPCR analysis
Cellular total RNA was extracted using TRIzol reagent
(Invitrogen Thermo Fisher) according to the manufac-
turer’s instructions. After digestion with RNase-free
DNase (Thermo Fisher), RNA was resuspended in
RNase-free water (Sigma-Aldrich) and retrotranscribed
(1 lg) using M-MLV reverse transcriptase (Promega,
Madison, Wisconsin, USA). For extraction of RNA
extract from murine pancreas, the tissue was immedi-
ately immersed in RNAlater (Thermo Fisher) and fro-
zen. After thawing, tissue was mechanically
homogenized by using the dispergierstation T8.10
(IKA WERKE, Staufen im Breisgau, Germany) and
RNA was isolated with RNeasy Mini Kit (Qiagen) and
treated with RNase-Free DNase Set (Qiagen, Hilden,
Germany). Twenty nanogram of cDNA was used as
template for both conventional PCR analysis (GoTaq,
Promega) and quantitative real-time PCR (qPCR)
analysis (SYBR Green, Roche, Basel, Switzerland). Pri-
mers used for PCR reactions are listed in Table S1.
2.6. Protein extraction and western blot
The pellet of cells was resuspended in lysis buffer
(150 mM NaCl, 15 mM MgCl2, 15 mM EDTA, 50 mM
Hepes, 10% Glycerol, 20 mM b-glicerophosphate, 1%
Triton X-100). Pancreatic tissue was extracted by
RIPA buffer (Tris/HCl 50 mM, NP40 1%, NaCl
150 mM, Na-Deoxycholate 0.5%, EDTA 2 mM, SDS
0.1%). Both buffers were completed with 1 mM dithio-
threitol, 2 mM Na-orthovanadate, and Protease Inhibi-
tor Cocktail (Sigma). After 10 min of incubation on
ice, extracts were sonicated at maximum intensity for
5 s and centrifuged for 10 min at 12000 g at 4 °C.
Supernatant fractions were resuspended in SDS/PAGE
sample buffer and boiled for 10 min.
For nuclear and cytoplasmic fractionation, cell pellets
were resuspended in modified lysis buffer (50 mM Tris/
HCl pH 7.5, 0.5% Triton X-100, 137.5 mM NaCl, 10%
Glycerol, 1 mM Na-orthovanadate, 50 mM Na-fluoride,
10 mM Na-pyrophosphate, 5 mM EDTA, and Protease
Inhibitor Cocktail). After incubation on ice for 15 min,
insoluble nuclei were separated by centrifugation at
13 000 r.p.m. for 15 min at 4 °C and the supernatant
(cytoplasmic fraction) collected. After rinsing once with
the lysis buffer, the nuclear pellet was resuspended in
the lysis buffer containing 0.5% SDS and released geno-
mic DNA sheared by sonication for 5 s at maximum
intensity. Then, extracts were centrifuged for 10 min at
12000 g at 4 °C, collect the supernatant (nuclear frac-
tion). Supernatants were resuspended in SDS/PAGE
sample buffer and boiled for 10 min.
Western blot analyses were performed as previously
described [31] using the following primary antibodies
(overnight at 4 °C): rabbit anti-MEX3A (1 : 1000,
HPA062703 Sigma), rabbit anti-ALDH1A3 (1 : 1000,
AP7847A Abgent, San Diego, California, USA), rabbit
anti-CDK6 (1 : 1000, D4S8S Cell Signaling, Carlsbad,
California, USA), goat anti-PTBP1 (1 : 1000, sc-16547
Santa Cruz Biotechnology), mouse anti-Actin
(1 : 1000, sc-47778 Santa Cruz Biotechnology, Dallas,
Texas, USA), and mouse anti-GAPDH (1 : 1000, SC-
32233 Santa Cruz Biotechnology). Secondary anti-
mouse or anti-rabbit IgGs conjugated to horseradish
peroxidase (Amersham, Little Chalfont, UK) were
incubated for 1 h at RT (1 : 10 000). Immunostained
bands were detected by chemiluminescence method
(Bio-Rad, Hercules, California, USA).
2.7. Cell viability assays
For MTS assay (Promega), cells were plated at 50%
confluence in 96 wells, and after 72 h of treatment, the
cell viability was evaluated by assessing the optical
density (OD) at 490 nm following the manufacturer’s
instructions.
For clonogenic assay, single-cell suspensions were pla-
ted in multiwell-6 (2000 cells/well). The next day, the cells
are treated, and after 10 days, cells were fixed in metha-
nol 100% for 10 min at room temperature, stained over-
night with crystal violet 0.05% (Sigma-Aldrich), washed
with H2O, and dried. Pictures were taken using a digital
camera to count and measure the colonies.
2.8. Cell cycle analysis
Cell cycle was evaluated by flow cytometry using single
staining with propidium iodide (PI) (20 mgmL1) or
double staining with PI and anti-BrdU antibody
(0.125 lg 9 sample), in the presence of ribonuclease A
(1 lgmL1) as previously described [32]. All cell cycle
phases were established using asynchronized control
samples. A total of 10 000 events were counted with
BD FACSCanto flow cytometer (Becton Dickinson,
Franklin Lakes, New Jersey, USA) and analyzed using
FLOWJO v.10 software (Becton Dickinson).
2.9. UV-crosslinked RNA immunoprecipitation
(CLIP) assay
CLIP assays were performed as previously described
[33] using the anti-FLAG antibody (3 lg) for
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immunoprecipitation 1 mg of cell extracts. RNA asso-
ciated with FLAG-MEX3A, or with control immuno-
precipitation, was represented as percentage of input.
2.10. RNA-sequencing analysis
For RNA-sequencing (RNA-seq) analysis, total RNA
was extracted using Qiagen RNeasy mini plus Kit
from MiaPaCa-2 cells transfected with Ctrl (n = 4),
MEX3A SP (n = 4) siRNA for 48 h.
The libraries were constructed by QuantSeq 30
mRNA. Differential gene expression was evaluated
after filtering out genes whose expression levels were
below 25 RPKM. Analysis for enriched Gene Ontol-
ogy functional clusters was performed using g:Profiler
(https://biit.cs.ut.ee/gprofiler/gost) and Enrichr (https://
amp.pharm.mssm.edu/Enrichr/).
3. Results
3.1. Identification of RNA processing regulators
associated with PDAC prognosis
To search for RNA processing regulatory factors that
may exert an impact on PDAC biology, we performed
an unbiased bioinformatic screening by querying The
Cancer Genome Atlas (TCGA) database for genes
associated with disease outcome in surgically resected
PDAC patients. We selected 204 genes encoding RBPs
and other proteins (i.e., kinases) that are involved in
RNA processing (i.e., splicing and/or cleavage and
polyadenylation, translation) (Table S2). Among them,
only 12 genes displayed a significant association with
DFS of PDAC patients. In some cases, high expres-
sion of the RBP associated with worse DFS (i.e.,
MEX3A and SRRM1), suggesting their potential
‘oncogenic-like’ function (Fig. 1A,B). By contrast,
other RBPs resembled ‘oncosuppressors’, as their high
expression levels associated with better prognosis (i.e.,
CELF3 and ELAVL3), (Fig. 1A,B). Moreover, analy-
sis of another PDAC dataset (http://r2.amc.nl –
Tumor Pancreatic adenocarcinoma-TCGA-178-rsem-
tcgars) indicated that ‘oncogenic-like’ factors (i.e.,
MEX3A and SRRM1) display positive correlation
with higher disease stage, whereas the opposite trend
was observed for ‘oncosuppressor-like’ factors (CELF3
and ELAVL3) (Fig. 1C). These observations suggest
that PDAC progression and outcome correlates with,
and may be affected by, a selected repertoire of RNA
processing factors.
Recent genome-wide sequencing analyses have indi-
cated the existence of two PDAC subtype, named
classical and basal-like [34]. Basal-like tumors are
characterized by a more aggressive clinical behavior
with respect to the classical subtype [28,29,31,34,
35,36], as also shown by DFS analysis (Fig. S1A).
Transcriptomic analysis of PDAC samples that were
screened for homogenous cancer cell population [29]
using the Psycomics tool [30] indicated that MEX3A,
and to a lesser extent SRRM1, were expressed at sig-
nificantly higher levels in basal-like tumors (Fig. 1D).
Accordingly, MEX3A expression was positively
correlated with markers of basal-like tumors [37],
such as KRT14 and KRT81 (Fig. 1E, Fig. S1B),
whereas negative (HNF4) or no correlation (GATA6)
was found with two markers of classical tumors
(Fig. 1F, Fig. S1C). These observations further corre-
late MEX3A expression with poor prognosis in
PDAC.
3.2. MEX3A expression is associated with
resistance to gemcitabine in PDAC cells
Poor prognosis in PDAC relies on rapid acquisition of
chemoresistance [3]. MEX3A was reported to mark an
intestinal stem cell population that is particularly
refractory to chemotherapeutic treatments [20]. More-
over, MEX3A protein expression was recently associ-
ated with poor prognosis in a cohort of PDAC
patients [21]. Thus, we focused our study on MEX3A.
To test the predictive value of our bioinformatic analy-
sis, we evaluated whether expression of MEX3A corre-
lates with drug resistance in PDAC cell lines. MEX3A
was expressed at higher transcript and protein levels in
the more malignant C5M2 and MiaPaCa-2 cells with
respect to less aggressive HPAF-II and ASPC1 cells
(Fig. 2A,B). Notably, HPAF-II cells were described as
classical PDAC subtype, whereas MiaPaCa-2 cells
clustered with basal-like PDAC [37]. We observed that
MEX3A was also expressed at much higher level in an
another basal-like cell line (PANC-1) than in the clas-
sical-like cell line Capan-1 (Fig. S2A) and that its
expression was inversely correlated with that of
GATA6 (Fig. S2B). These results further suggest that
MEX3A expression is associated with the basal-like
PDAC subtype.
Viability assays using two doses of gemcitabine, a
drug frequently included in first-line chemotherapeutic
treatments for PDAC [3], confirmed that cells express-
ing higher levels of MEX3A are more resistant to
treatments than low-expressing cells (Fig. 2C). To
investigate whether MEX3A contributed to drug resis-
tance in PDAC cells, we silenced its expression by
RNA interference (RNAi). MEX3A depletion using
two different siRNAs significantly enhanced sensitivity
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to gemcitabine over a range of drug concentrations in
both MiaPaCa-2 (Fig. 2D–F) and C5M2 cells
(Fig. S2C,D).
Next, we generated drug-resistant clones (MiaPaCa-
2-DR) by exposure of MiaPaCa-2 cells to treatment
with 1 lM gemcitabine for 7 days. At the end of the
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selection, surviving clones were isolated and amplified
under recurring monthly treatments with the drug to
maintain the selection. To confirm the phenotype of
MiaPaCa-2-DR cells, we analyzed cell survival by
clonogenic assays. While exposure to gemcitabine
reduced the number of colonies in a dose-dependent
manner in parental MiaPaCa-2 cells, DR cells were
insensitive to treatments (Fig. 2G). Importantly,
MEX3A expression was further increased in MiaPaCa-
2-DR cells with respect to parental cells (Fig. 2H).
Furthermore, a similar up-regulation of MEX3A was
also observed in another clone of drug-resistant PDAC
cells that we previously established (Pt45P1-DR;
Fig. S2E) [14]. These results support a functional role
for MEX3A in the acquisition and maintenance of













































































































































































Fig. 2. MEX3A promotes resistance to gemcitabine in PDAC cells. (A, B) Analyses of MEX3A expression in PDAC cells by qPCR (A) and
western blot (B). Data were normalized for L34 (A) and GAPDH (B) expression. (C) Percentage of survival evaluated by MTS assay after
72 h of treatment with two doses of gemcitabine (0.6 and 1 lM) in PDAC cells. Statistical analyses are reported in light blue when is
referred to HPAF cells, while in blue when is referred at ASPC1 cells. (D, E) Analyses of MEX3A expression by qRT-PCR (D) and western
blot (E) to evaluate depletion of the transcript and protein after silencing with siMEX3A-1 or smartpool (sp) siRNAs. (F) Percentage of
survival evaluated by MTS assay after 72 h of treatment with the indicated doses of gemcitabine in MiaPaCa-2 cells transfected with CTRL,
MEX3A-1 or MEX3A-sp siRNAs. (G) Clonogenic assay to evaluate survival of the parental and drug-resistant (MP-DR) MiaPaCa-2 cells in the
presence of the indicated doses of gemcitabine. (H) Western blot of MEX3A expression in MP-2-DR and parental MiaPaCa-2 cells.
Statistical analyses were performed by one-way ANOVA (A, D, G) and two-way ANOVA (C, F). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Fig. 1. RNA processing regulators associated with PDAC prognosis. (A) RBPs and kinases whose expression is significantly correlated with
DFS in PDAC patients annotated in TGCA database. Genes are grouped as potential oncogenes and oncosuppressors on the basis of their
association with DFS. HR [CI 95%] indicates the hazard risk of COX regression. (B) Kaplan–Meier curve of DFS for MEX3A and SRRM1
(oncogenic-like factors) and CELF3 and ELAVL3 (oncosuppressor-like factors) in PDAC patients. (C) Box-plot analysis displaying correlation
between expression levels and disease stage in PDAC patients for ‘oncogenic-like’ factors (i.e., MEX3A and SRRM1) and ‘oncosuppressor-
like’ factors (CELF3 and ELAVL3). (D) Density plot of MEX3A and SRRM1 gene expression in PDAC patients from TCGA that were
classified as basal-like or classical subtype according to Moffitt’s classification. Dotted lanes indicate the median gene expression value in
the two groups of patients. (E, F) Scatter plot of Pearson’s correlation analysis of MEX3A and KRT81 (E) or HNF4A (F) performed using the
cBioPortal database. Statistical analyses were performed by multivariate Cox proportional hazard regression model (A, B), one-way ANOVA
(C) and Welch two-sample t-test (D).
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3.3. MEX3A expression is increased in a mouse
model of PDAC
Activating mutations in KRAS represents the most
common genetic driver of PDAC, which is found in
up to 90% of patients [38]. Moreover, introduction of
mutations in Kras is sufficient to cause tumorigenesis
in mice [25]. To test whether MEX3A expression was
modulated during neoplastic transformation of pancre-
atic cells, we employed the LSL-KrasG12D/+ Pdx-1-Cre
PDAC mouse model, which is characterized by condi-
tional expression of an oncogenic Kras mutant allele in
the pancreas [26]. In particular, we used a mouse
model crossed with the MITO-Luc mouse, which
expresses the luciferase reporter gene under the control
of a mitotic promoter. In the resulting MITO-Kras-
Cre (MKC) mice, physiological and aberrant cell pro-
liferation in the organ can be measured by noninvasive
bioluminescence imaging (BLI) (Fig. 3A) [28]. Pancre-
atic tissue was collected from MKC or control mice
(MC) at 19–28 weeks of life when abdominal BLI was
significantly increased (Fig. 3B), and strong lumines-
cence could be readily detected in the pancreas ex vivo
(Fig. 3C; Fig. S3A). Quantitative real-time PCR
(qPCR) analysis revealed that MEX3A was barely
detectable in normal tissue, whereas its expression was
significantly increased in the pancreas isolated from
MKC mice (Fig. 3D). Moreover, western blot analyses
of pancreatic tissue from MKC mice indicated that
MEX3A protein is up-regulated in the pancreas that
has developed a tumor with respect to control mice
(Fig. 3E-F; Fig. S3B). These observations suggest that
MEX3A may contribute to PDAC tumorigenesis.
3.4. MEX3A regulates genes involved in cell
cycle progression
MEX3A has been previously involved in the stability
of specific transcripts [39]. However, no information is
currently available on the genome-wide impact of
MEX3A on the cell transcriptome. To investigate its
functional role in PDAC cells, we performed RNA-se-
quencing (RNA-seq) analysis of MiaPaCa-2 cells
depleted of MEX3A. RNA was extracted after 48 h,
when MEX3A was efficiently down-regulated at tran-
script level (Fig. 4A) and used for the RNA-seq analy-
sis. By screening for transcripts displaying ≥ 25
RPKM and fold change ≥ 2, we identified 726 genes
that were significantly regulated (P < 0.05) by deple-
tion of MEX3A in MiaPaCa-2 cells. The majority of
the MEX3A-sensitive genes (484, 65%) were down-
regulated (Fig 4B, Table S3). Functional clustering
analysis identified ‘cell cycle’, ‘Hippo signalling’, and
‘TGF-beta signaling’ as pathways enriched among the
down-regulated genes, whereas up-regulated genes
were more heterogeneous, with only three functional
categories related to ‘proteasome’ and ‘pathogenic
infections’ being enriched (Fig. 4C). Direct qPCR
analysis of the expression of MEX3A-regulated genes
(TCF7, CDK6, TEAD2, ALDH1A3, PTBP1, and
SF3A1) confirmed the results of the RNA-seq
(Fig. 4D), thus validating the bioinformatic analysis.
Moreover, western blot analysis of PTBP1, ALDH1A3
and CDK6 showed concomitant reduction at the pro-
tein level (Fig. 4E), whereas all these targets were
expressed at higher level in DR-MiaPaCa-2 cells
(Fig. S4). Importantly, analysis of pancreas from
MKC mice documented increased expression of two of
these MEX3A target genes (i.e., Ptbp1 and Aldh1a3) at
both mRNA and protein levels with respect to tissues
from control mice (Fig. 4F,G).
3.5. MEX3A binds its target transcripts and
regulates their stability
Dysregulation of the Hippo pathway plays a key role
in PDAC tumorigenesis [40], whereas inhibition of the
cell cycle kinases CDK4 and CDK6 represents a
promising therapeutic approach for PDAC [22]. Thus,
genes that require MEX3A for their expression play
oncogenic functions in PDAC. To further investigate
how MEX3A regulates its target transcripts, we first
evaluated its subcellular distribution in MiaPaCa-2
cells. MEX3A was reported to shuttle between nucleus
and cytoplasm in other cell types [41]. Transfection of
the recombinant protein MEX3A-GFP indicated that
MEX3A is predominantly cytoplasmic in MiaPaCa-2
cells (Fig. 5A). Subcellular fractionation analyses con-
firmed this result and indicated that both the recombi-
nant MEX3A-GFP protein and the endogenous
MEX3A were prevalently localized in the cytoplasm of
MiaPaCa-2 cells (Fig. 5B,C). Thus, we tested whether
MEX3A regulates expression of its target transcripts
at the post-transcriptional level.
First, we asked if MEX3A directly interacts with its
target mRNAs. To this end, we performed UV-cross-
link and RNA immunoprecipitation (CLIP) assay in
MiaPaCa-2 cells over-expressing FLAG-MEX3A or
transfected with empty vector. A strong enrichment of
CLIP signals for TCF7, CDK6, and other MEX3A-
regulated transcripts was detected in the MEX3A
immunoprecipitates with respect to control samples
(Fig. 5D; Fig. S5A).
To test whether MEX3A modulates the half-lives of
its target transcripts, we performed stability assays in
live cells. MiaPaCa-2 cells were treated with
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Actinomycin D to block transcription, and decay of
transcripts was measured by qPCR at different time
points. Importantly, depletion of MEX3A significantly
accelerated the decay of CDK6 and TCF7 mRNAs in
MiaPaCa-2 cells (Fig. 5E), whereas it did not affect a
control, non-regulated gene (Fig. S5B). These results
suggest that MEX3A regulates gene expression by
directly binding to target mRNAs.
3.6. MEX3A affects cell cycle progression in
PDAC cells
Regulation of the cell cycle emerged as one of the
main pathways regulated by MEX3A in PDAC cells.
Thus, we investigated the impact of MEX3A expres-
sion on cell cycle progression. Synchronization of Mia-
PaCa-2 cells by mimosine-induced block [24] indicated
that MEX3A expression is regulated during the cell
cycle, being higher in G1 and decreasing in the subse-
quent S phase (Fig. 6A–C). Moreover, depletion of
MEX3A in MiaPaCa-2 cells caused a significant
reduction in proliferation, as measured by colony for-
mation assay, cell counting and proliferation assay
(Fig. 6D–F). Notably, FACS analysis showed that
MEX3A depletion causes a significant enrichment in
G1 and reduction of S phase already after 24 h, a phe-
notype that was more dramatic after 48 h from silenc-
ing (Fig. 6G).
The Cyclin D1/CDK6 complex promotes the G1/S
transition of the cell cycle [42]. Since CDK6 is reduced
in MEX3A-depleted cells, we tested whether MEX3A
was required for S phase entry. Following synchro-
nization in G1 by mimosine treatment, cells were
released and cell cycle progression was monitored by
FACS analysis. Strikingly, MEX3A-depleted Mia-
PaCa-2 cells remained stalled in the G1 phase after
release from the drug, whereas most control cells pro-
gressed to the S phase by 6 h and entered in the G2
phase of the cycle by 18 h (Fig. 7A,B). These findings
suggest that MEX3A expression is required for the
completion of the G1 phase and the transition into the







































































































Fig. 3. MEX3A expression is increased in a mouse model of PDAC. (A) Longitudinal monitoring of PDAC-associated proliferation by in vivo
BLI. Representative images of representative MKC and control MC mice were taken at the indicated weeks. (B) Bar graph showing the
mean of the abdominal bioluminescence of MKC (n = 3) and MC (n = 3) mice at the indicated experimental time points. (C) Representative
ex vivo BLI image of the isolated pancreas from MC and MKC mice shown in panel B. (D, E) Analysis by qPCR (D) and western blot (E) to
evaluate MEX3A expression level in MKC and MC mice. (F) Densitometric analysis of MEX3A protein expression levels (n = 5 for MC mice
and n = 9 for MKC mice). Data were normalized for Actin intensity. Statistical analyses were performed by Student’s t-test (C–F). *P ≤ 0.05.
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4. Discussion
Pancreatic ductal adenocarcinoma has emerged as a
clinical priority in oncology in the last decade [1], due
to its extremely poor prognosis and refractoriness to
therapies [3]. Indeed, PDAC is predicted to become
the second cause of death for cancer by 2030 [43]. As
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Fig. 4. MEX3A regulates genes involved in cell cycle progression in PDAC cells. (A) Analysis by qRT-PCR of MEX3A expression in MiaPaCa-
2 cells transfected with MEX3A-sp siRNAs or control siRNAs and used for the RNA-seq experiment (n = 4). (B) Pie chart of genes that are
up- and down-regulated in MiaPaCa-2 cells depleted of MEX3A identified by the RNA-seq analysis. (C) Gene ontology (KEGG) of up- and
down-regulated genes in MiaPaCa-2 cells depleted of MEX3A performed by using the g-profiler web server. (D) Validation by qRT-PCR of
the effect of MEX3A depletion on selected target genes. MEX3A depletion was performed by using two separate siRNA sets (siMEX3A-1
and siMEX3A-sp). (E) Western blot analysis of the expression of MEX3A targets (PTBP1, ALDH1A3 and CDK6) in MiaPaCa-2 cells. (F, G)
Analysis by qPCR (F) and western blot (G) of the expression of MEX3A target genes (Ptbp1 and Aldh1a3) in MKC and MC mice. Statistical
analyses were performed by Student’s t-test (A–F) one-way ANOVA (D). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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likely that a better understanding of PDAC biology
will be instrumental for the identification of new thera-
peutic targets and for the development of innovative
therapies that counteract acquisition of chemoresis-
tance. In this study, we show that MEX3A is up-regu-
lated in PDAC patients and associates with poor
prognosis. MEX3A binds to and modulates the expres-
sion of hundreds of mRNAs in PDAC cells, particu-
larly those encoded by cell cycle genes. Moreover,
MEX3A promotes resistance to gemcitabine, which is
frequently used either alone or in combination with
nab-paclitaxel as first-line chemotherapeutic treatment
for PDAC, suggesting a direct role for this RBP in the
acquisition of a drug-resistant phenotype.
Aberrant expression of RBPs is a common phe-
nomenon during development and progression of
human cancers. Dysregulated RBPs often promote
oncogenic isoforms that affect cell cycle regulation, cell
proliferation, and invasion [46]. Our bioinformatic
screen aimed at identifying RBPs associated with
disease outcome in PDAC yielded only 12 out of 204
genes with significant correlation, of which only five
were associated with poor prognosis. This relatively
small number of genes may be due to the small cohort
of PDAC patients (n = 112) for which full data are
available in the TCGA database. Nevertheless, to vali-
date the reliability of our predictive analysis we
focused on MEX3A, because this RBP was recently
shown to mark intestinal stem cells that are refractory
to chemotherapeutic treatments [20]. This observation
attracted our attention because subpopulation of can-
cer cells that are particularly resistant to chemothera-
peutic treatments are thought to guide relapse of
disease in many cancers, including PDAC [47]. More-
over, a recent screening of 1542 human RBPs dysregu-
lated across 15 cancer types indicated that MEX3A is
up-regulated in multiple epithelial cancers [46]. Never-
theless, relatively little is known on the oncogenic
functions of MEX3A and even less on the molecular





































































































Fig. 5. MEX3A binds its target transcripts and regulates their stability. (A) Immunofluorescence analysis of the MEX3A-GFP recombinant
protein; scale bar = 57 lm. (B, C) Subcellular fractionation analyses of recombinant MEX3A-GFP protein (B) and endogenous MEX3A (C). (D)
Bar graphs showing the results CLIP assays performed by anti-FLAG immunoprecipitates of extracts from MiaPaCa-2 cells transfected with
either empty FLAG plasmid or FLG-MEX3A plasmid. Data represent qPCR analyses of TCF7 and CDK6 mRNAs co-precipitated in CLIP
experiments and are normalized as percentage of input. (E) TCF7 and CDK6 transcript stability after depletion of MEX3A and treatment with
Actinomycin D for the indicated time. The qPCR analyses were normalized to GAPDH mRNA levels and by setting the T0 value as 100%.
Statistical analyses were performed by Student’s t-test (D) and two-way ANOVA (E). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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Up-regulation of MEX3A in gastric tumor tissues was
previously shown to promote cell proliferation and
migration, but the mechanism involved was not
investigated [23]. Furthermore, while this work was in
progress, another study reported the up-regulation of
MEX3A protein in PDAC patients correlated with
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Fig. 7. MEX3A acts on transition G1/S phase of cell. (A) FACS analysis showing DNA content (PI) of MiaPaCa-2 cells after release from
mimosine synchronization in cells transfected with CTRL or MEX3A siRNAs. (B) Bar graphs show the percentage of cells in G1, S, and G2
phase of cell cycle by FACS analysis of panels shown in (A). Statistical analyses were performed by two-way ANOVA (B). **P ≤ 0.01,
***P ≤ 0.001.
Fig. 6. MEX3A regulates cell cycle progression in PDAC cells. (A) FACS analysis showing DNA content (PI) of MiaPaCa-2 cells after release
from mimosine-induced synchronization. Times were chosen for enrichment of cells in the G1 and S phases of the cycle. (B, C) Analyses by
qPCR (B) and western blot (C) of MEX3A expression in G1 and S phase cells. (D) Clonogenic assay performed in MiaPaCa-2 cells
transfected with CTRL or MEX3A siRNAs. Colonies were counted after 10 days from seeding. (E) Analysis of cell proliferation of MiaPaCa-2
cells transfected with CTRL or MEX3A siRNAs. Data are represented as percentage of growth of control cells after 72 h. (F) MTS assay
after of MiaPaCa-2 cells transfected with CTRL or MEX3A siRNAs. Data are represented as fold increase at 72 h with respect to time of
seeding (T0). (G) FACS analysis showing DNA content (propidium iodide, PI) and bromodeoxyuridine (BrdU) incorporation of MiaPaCa-2 cells
transfected with CTRL or MEX3A targeting siRNAs at 24 or 48 h. The percentage of cells in G1, S, and G2 phase are indicated. Statistical
analyses were performed by the Student’s t-test (B, D, E) or two-way ANOVA (F, G). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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poor prognosis, whereas depletion of MEX3A in
PDAC cells inhibited proliferation and migration
in vitro and tumor development in mouse xenograft
model [21]. However, no insight into the mechanism
through which MEX3A elicited these effects was pro-
vided. Herein, by using two different PDAC cell lines,
we confirmed the effect of MEX3A expression on pro-
liferation and colony formation. We observed that
MEX3A transcript and protein levels are increased in
PDAC cells displaying a basal-like phenotype, which
has been associated with worse prognosis in PDAC
patients [33,34,35]. Moreover, MEX3A was up-regu-
lated in vivo in a mouse model of pancreatic tumorige-
nesis. Our transcriptomic analysis has also identified
hundreds of genes whose expression is susceptible to
MEX3A levels in PDAC cells. Notably, we found a
significant enrichment in cell cycle and Hippo pathway
genes, two functional categories of relevance for
PDAC biology [20,29]. Interestingly, MEX3A pro-
moted the expression of genes involved in these path-
ways also in stem cells of the intestinal crypts [48],
corroborating our results. It is also worth mentioning
that MEX3A appears essential for the maintenance of
intestinal stem cells in vivo [39]. This observation,
together with the similarity in genes regulated by this
RBP in intestinal stem cells and PDAC cells, suggests
that high expression of MEX3A may confer stem-like
features to PDAC cells, which are known to be associ-
ated with refractoriness to chemotherapeutic treat-
ments. Our data are in line with this hypothesis, as
depletion of MEX3A increases susceptibility to gemc-
itabine, whereas its expression is up-regulated upon
chronic exposure to the drug. These results suggest
that targeting MEX3A may represent a valuable
approach to improve the efficacy of the current
chemotherapeutic treatments for PDAC.
We found that MEX3A is prevalently localized in
the cytoplasm of PDAC cells, binds directly to its tar-
get transcripts, and promotes their stability. This
action on the stability of transcripts has also been
found for MEX3B, a member of the MEX3 family
with high structural homology to MEX3A. MEX3B
was shown to bind the 30 untranslated region of the
BIM mRNA, thus competing with access to miRNAs
and leading to up-regulation of BIM expression and
induction of cell death [49]. Binding of MEX3A to its
target transcript may also underlie its effect of the phe-
notype of PDAC cells. For instance, we observed that
MEX3A binds to and stabilizes CDK6 mRNA levels.
CDK6 is a cyclin D-associated kinase that promotes
the transition between G1 and S phase of the cell
cycle. CDK6 expression levels are significantly reduced
in MEX3A-depleted PDAC cells, and this effect
correlates with a specific defect of MEX3A-depleted
cells to exit from the G1 phase and enter into the S
phase. Thus, the RNA-binding activity of MEX3A
may exert a physiological impact on PDAC cell biol-
ogy, similarly to what was reported for its homolog
MEX3B. Importantly, CDK6 is a suitable target for
PDAC, as mutations in its physiological inhibitor
p16INK4A, encoded by the CDKN2A tumor suppres-
sor gene, are the second most frequent genomic aber-
ration in found PDAC patients [3]. Moreover,
inhibitors of CDK4 and CDK6 activity, the two
kinases that associate with cyclin Ds to drive entry
into S phase, have been recently shown to exert a
strong effect in PDAC when combined with conven-
tional chemotherapeutic treatments [20]. We now
report that MEX3A also promotes the expression of
PTBP1, an RBP that was previously shown to con-
tribute to acquisition of a drug-resistant phenotype in
PDAC [14]. These observations suggest that MEX3A
may also affect therapeutic treatments of PDAC
through the regulation of target genes involved in pro-
cesses and pathways highly relevant for this disease,
such as cell cycle regulation and Hippo pathway.
5. Conclusions
In conclusion, our study identifies MEX3A as an RBP
involved in PDAC, whose high expression correlates
with poor prognosis. Furthermore, our study also indi-
cates that MEX3A is a novel biomarker associated
with the basal-like PDAC subtype. These findings sug-
gest that MEX3A represents a key oncogenic factor
and, possibly, a new therapeutic target for PDAC
treatment.
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Fig. S1. A) Kaplan-Meier curve of DFS for basal and
classic subtype of pancreatic cancer in PDAC patients.
Statistical analyses were performed by log rank test.
B-C) Scatter plot of Pearson’s correlation analysis of
MEX3A and KRT14 (B) or GATA6 (C) performed
using the cBioPortal database.
Fig. S2. A) Analysis by qPCR of MEX3A (A) and
GATA6 (B) expression levels in PDAC cell lines. C)
Analysis by qPCR of the MEX3A expression levels in
C5M2 cells transfected with the indicated siRNAs. D)
Percentage of survival evaluated by MTS assay after
72h of treatment with different doses of gemcitabine in
C5M2 cells transfected with CTRL, MEX3A or
MEX3A SP siRNAs. E) Western blot analysis of
MEX3A expression in PT45P1-DR cells. Statistical
analyses were performed by one way Anova (A-B-C)
and two way Anova (D).
Fig. S3. A) Ex-vivo images of the isolated pancreas of
MC and MKC mice performed by BLI. B) Western
blot analysis of MEX3A protein expression in MKC
and MC mice.
Fig. S4. Western blot analysis of the expression of
MEX3A targets (PTBP1, ALDH1A3 and CDK6) in
MP-2-DR and parental MiaPaCa-2 cells.
Fig. S5. A) Bar graphs shows the results of qPCR
analyses of TEAD2, ALDH1A3, PTBP1 and SF3A1
mRNAs co-precipitated by FLAG antibody in CLIP
experiments. The samples are normalized with respect
to input. B) L34 transcript stability after depletion of
MEX3A and treatment with Actinomycin D for the
indicated time.
Table S1. List of PCR primers.
Table S2. List of RNA processing genes analyzed.
Table S3. List of genes regulated in MEX3A-depleted
cells.
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